Bioactive Glass Inhibits Tumor Development from Giant Cell Tumor of Bone-Derived Neoplastic Stromal Cells in a

Joerg Fellenberg1, Sarina Losch1, Max R Marinescu1

  • 1Experimental Orthopaedics, Department of Orthopaedics, Heidelberg University Hospital, 69118 Heidelberg, Germany.

Cancers
|March 29, 2023
PubMed

Insights

Bioactive glasses (BGs) show cytotoxic effects against giant cell tumor of bone (GCTB) cells. In vivo studies confirmed BGs reduce GCTB recurrence and promote bone regeneration, suggesting a potential clinical application.

Area of Science:

  • Biomaterials Science
  • Oncology
  • Orthopedic Surgery

Background:

  • Giant cell tumors of bone (GCTB) frequently recur after treatment.
  • Bioactive glasses (BGs) have demonstrated in vitro cytotoxic effects on GCTB stromal cells (GCTSCs).

Purpose of the Study:

  • To evaluate the in vivo efficacy of BGs in treating GCTB.
  • To assess the potential of BGs in reducing tumor recurrence and promoting bone regeneration.

Main Methods:

  • In vitro cytotoxicity assays (WST-1) of three BGs against GCTSCs.
  • In vivo chicken chorioallantoic membrane (CAM) assays to analyze BG effects on tumor engraftment and growth.
  • Quantification of tumor take rates and volumes in BG-treated samples.

Main Results:

  • All tested BGs exhibited concentration-, composition-, and particle size-dependent cytotoxicity against GCTSCs in vitro.
  • In vivo CAM assays showed reduced tumor take rates and volumes in BG-treated groups.
  • Bioactive glasses demonstrated comparable cytotoxic effects in vivo as observed in vitro.

Conclusions:

  • Bioactive glasses show promise as an adjuvant therapy for GCTB, reducing recurrence rates.
  • BGs may offer a dual benefit of inhibiting tumor growth and promoting bone regeneration in GCTB treatment.

Related Concept Videos